H
istorically, pharmacologists developed drugs by focusing on discrete, biologically isolated targets: the betaadrenergic receptor, angiotensinconverting enzyme or a calcium channel, for example. Genomics and molecular biology increased pharmacologists' accuracy, exemplified by the growing number of cancer drugs that target specific kinases or particular aberrant proteins in malignant cells. But despite its track record, reductionist pharmacology doesn't hold all the answers.
After all, biology is more than a catalogue of genes and proteins. So, researchers can't always predict outcomes by analysing the components involved. Indeed, the biological world is a hierarchy beginning with subatomic particles (such as the transport of electrons in metabolic chains) and ending in, for example, the biosphere. Each level has 'emergent phenomena' -such as mental functions, consciousness and even life -that cannot be predicted from the lower levels. 1 In other words, a diagram of the interconnections between genes and proteins "is analogous to a static roadmap, whereas what we really seek to know are the traffic patterns, why such traffic patterns emerge, and how we can control them." 2 Systems biology aims to help biologists move from static maps to dynamic representations. "Systems biology recognises that living systems and disorders, such as cancer, are integrated systems of components rather than isolated molecular processes or dysregulation events," says Aaron Meyer, assistant professor, Department of Bioengineering at the University of California, Los Angeles.
Systems biology: transforming our understanding of disease
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Systems biology -the study of complex biological systems using computer modelling -is beginning to transform our understanding of disease processes, which will in turn facilitate medical treatment and drug development. Mark Greener discusses how systems biology has already advanced our knowledge of conditions as diverse as cancer, pressure ulcers and sexuallytransmitted disease. Systems biology l RESEARCH ■ Indeed, systems biology is beginning to "revolutionize our understanding of complex biological regulatory systems", 2 including those that underlie common diseases. Improved understanding will, in turn, enhance drug development, facilitate beneficial polypharmacy and allow prescribers to target treatment more accurately to patient subgroups.
More than the sum of its parts
Fundamentally, systems biology reflects the old adage that the whole is greater than the sum of its parts. "Let's say you go to a restaurant. You liked the food and ask the chef for the ingredients. The next day you go online and learn about each ingredient. You put together all the ingredients in the exact same quantity as listed by the chef. But, the meal is not even close to what you had at the restaurant," says Gaurav Kandoi, a computational biologist at Iowa State University. "You furiously return to the restaurant. Smiling, the chef explains how you added lime before letting the previous herb cook. The lime reacted with the raw herb to completely change the flavour. Had you studied the ingredients as a system, considering the effect of one ingredient on every other ingredient, your dish would have been as delicious as the original. The molecules within our cells are the ingredients that come together to form our body's complex machinery. Systems biology looks at how these molecules work together."
The "big picture" offered by systems biology, Mr Kandoi explains, "leads to a higher level of understanding in complex and multifactorial diseases and fasttracks the identification of dysregulated molecular pathways while discovering novel prognostic and diagnostic biomarkers that can be used for therapeutics development." As part of this, systems biology uses sophisticated computer representations -so-called in silico modelling -of, for instance, intracellular pathways, microenvironmental networks in cancer or damaged tissues, and whole cells to improve the accuracy of predictions compared with traditional reductionist approaches. Researchers can even run 'virtual clinical studies'.
For example, combining machine learning -a type of artificial intelligence that allows programs to learn and make increasingly accurate predictions as data accumulates without a change in programming -and systems biology can distinguish specific properties of druggable versus non-druggable targets or an enzyme versus a non-enzymatic protein. 3 "Like other sciences, systems biology is limited by the current computing and algorithmic resources and a lack of adequate biological knowledge," Mr Kandoi says. "However, while we still haven't been able to simulate a complete disease using an in silico model, we've come a long way."
Pressure ulcers and sexuallytransmitted disease
Up to 80% of people with spinal cord injuries develop pressure ulcers. Pressure ulcers arise when injury triggers acute inflammation, which involves the dynamic, integrated action of numerous specialised cells -including platelets, mast cells, macrophages and neutrophils -and a complex cocktail of inflammatory cytokines, free radicals and damageassociated molecular pattern (DAMP) molecules. This inflammatory response can heal the damaged tissue or become dysfunctional leading to a chronic pressure ulcer. Understanding the pathways and the mediators could lead to new management approaches for this notoriously difficult-to-treat condition. However, the underlying complexity and the fact that the biological effects produced by a particular pathway or mediator depend on timing and context makes identifying targets problematic using conventional approaches 4 -and that's where systems biology and an in silico model come in.
The in silico model begins by representing differences in pressure over a bony prominence and the surrounding tissue as well as the interplay between the various cells and molecules. As the model develops 'over time', the simulated ulcers are visually similar to clinical ulcers in people with spinal cord injury. In particular, the simulated ulcers showed similar irregular shapes, jagged edges and overall progression to their clinical counterparts. The model confirmed that inflammation is important in determining ulcer severity and tissue damage. Despite this, simulated clinical trials revealed that corticosteroids and an antibody that neutralises DAMPs can reduce local inflammation and tissue damage that arise from the pressure. But these anti-inflammatory approaches did not reduce the incidence of pressure ulcers and to have any chance of working must be applied early, even before many signs of clinical ulceration emerge. 4 Recently, researchers developed a computer model of the lifecycle of the bacterium Mycoplasma genitalium (see Figure 1 ), a common cause of sexuallytransmitted disease (STD). The model reproduced the whole bacterial cell, including all 525 genes, the other molecular components and their interactions. The model accurately reproduced a broad set of previous experimental data and offered insights into several biological processes where conventional approaches are difficult, such as determining the in vivo rate of associations between proteins and DNA. The model also rapidly identified gene functions and helped uncover previously undetected biological functions. 5 "My biggest hope for systems biology is that we will be able to create more realistic whole cell models," Mr Kandoi says.
" I hope and expect that systems biology will begin to provide clinical benefits to patients by identifying new drug combinations and identifying appropriate patient populations.
Aaron Meyer, assistant professor, Department of Bioengineering, University of California "
Modelling cancer
In cancer, Professor Meyer and colleagues commented in a recent paper, systems biology aims to understand malignancies as "an integrated system of genes, networks, and interactions rather than an entity of isolated molecular and cellular components". 6 But understanding cancer's molecular features often uncovers unappreciated layers and forms of complexity. Nevertheless, computer models are increasingly capable of simulating this complexity. One model, for example, used "open data in publications that span years of research, scientific disciplines, and experimental systems" to predict the signalling pathways that are active during the epithelial-to-mesenchymal transition in cancer. 6 This process transforms epithelial cells held together to form a tissue into more mobile forms that can invade the surrounding organ and metastasise. Using systems biology to understand the communications within and between cells in the 'microenvironment' around the tumour will also help realise immunotherapy's full potential. 6 (As Prescriber reported previously, immunotherapy is an important advance in cancer treatment. 7 ) In the meantime, Professor Meyer notes, systems biology has helped reveal molecular subtypes of cancers. "This molecular subtyping has helped clarify the relationship between individual tumours of similar and different tissues of origin," he explains. "Subtyping cancer according to molecular measurements has shown that cancers of differing origin can be strikingly similar and that these subtypes may be superior for identifying which patients will respond to therapies." In addition, systems-level approaches have helped elucidate the mechanisms through which resistance emerges to targeted cancer therapies. Systems biology and in silico modelling can show how, for instance, metabolic changes in breast cancer influence the response to drugs. 6 "We now know that heritable and non-heritable intra-tumour heterogeneity, molecular feedback and other processes limit the benefit of these therapies, and approaches to counteract these limitations are under clinical investigation," Professor Meyer says.
The end of traditional drug development?
None of this, however, means the demise of traditional drug development. Systems biology and the traditional approaches form "a continuous spectrum of knowledge".
2 "It's only possible to understand biological systems in an integrated fashion with a 'parts list' of the important pieces," remarks Professor Meyer. "Systems biology also provides answers to a particular type of question that only partly overlaps with reductionist approaches. Both are strongly complementary and necessary." "Although the system as a whole has more information than the individual molecules, we still require the basic understanding of how each of these molecules work," agrees Mr Kandoi. "Medical conditions have different physiologies and while the systems approach will help us uncover the holistic mechanisms, the technologies of molecular medicine and pharmacology are required to study the key molecular determinants that affect human conditions and diseases in greater detail." Furthermore, translating insights from systems biology into clinical outcomes and new drugs can pose a challenge. "For reductionist approaches, the translation is often clearer -for example, protein X modulates disease, and so one should measure or manipulate protein X," Professor Meyer says. "Systems biology often deals with multiple components, however, and so there is an added barrier to applying these findings. On the diagnostic side, easier, cheaper and more quantitative methods of measuring multiple molecular factors could aid translation. When it comes to drug development, approaches to rationally manipulate polypharmacology and experience exploring drug combinations would help. I hope and expect that systems biology will begin to provide clinical benefits to patients by identifying new drug combinations and identifying appropriate patient populations." Indeed, over the next few years, Professor Meyer expects to see a "blurring of the line between systems biology and reductionist approaches" to biology and drug development. "Improved molecular characterisation has made it abundantly clear that even seemingly 'simple' interventions operate through myriad molecular consequences," he says. "At the same time, the level of characterisation now feasible makes it possible to routinely apply systems approaches in molecular biology. My hope is this will only improve the rigour of our understanding of cancer since these systems-level changes are sometimes implicitly ignored in reductionist studies." "Systems biology is like a chef's paradise, in which the chef has access to unlimited ingredients and it is up to their creativity to try out different recipes and come up with the understanding of why some recipes work, while others don't," Mr Kandoi concludes. "It is not the technical limitations that limit the potential of systems biology, but pioneering visionaries, collaborative teams and conceptual advances."
